Trials / Unknown
UnknownNCT06195124
A Study on the Safety and Tolerability of RGL-193 in Patients With Advanced Parkinson's Disease
A Study on the Safety and Tolerability of RGL-193 Injection in Patients With Advanced Parkinson's Disease - An Open-label and Dose-escalation Clinical Trial
- Status
- Unknown
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 8 (estimated)
- Sponsor
- Second Affiliated Hospital of Soochow University · Academic / Other
- Sex
- All
- Age
- 45 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
A safety study in patients with Parkinson's disease.
Detailed description
This is an open-label, dose-escalation safety and tolerability study in patients with advanced Parkinson's disease
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RGL-193（low-dose） | Each side of the putamen received 150 μL of RGL-193, with a unilateral dose of 1.5×10\^11 VG and a bilateral dose of 3.0×10\^11 VG. |
| DRUG | RGL-193（high-dose） | Each side of the putamen received 200 μL of RGL-193, with a unilateral dose of 5.0×10\^11 VG and a bilateral dose of 1.0×10\^12 VG. |
Timeline
- Start date
- 2023-12-01
- Primary completion
- 2024-12-01
- Completion
- 2024-12-01
- First posted
- 2024-01-08
- Last updated
- 2024-03-15
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06195124. Inclusion in this directory is not an endorsement.